Chordate Medical recently announced subgroups results from the company’s migraine study showing a statistical significant reduction in number of headache days in patients receiving active K.O.S. treatment compared to the subjects receiving the sham treatment. An abstract with the results is presented at the Migraine Trust International Symposium 2022 in London. BioStock took the opportunity to interview Dr Jan Hoffmann, author of the abstract.
Watch the interview with Dr Hoffmann from King’s College London below: